TimeScale Financial’s GT Biopharma GTBP Stock Holding History

TimeScale Financial’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$171	Hold	18	–	–	﹤0.01%	608
2023 Q1	$302	Hold	18	–	–	﹤0.01%	584
2022 Q4	$966	Hold	18	–	–	﹤0.01%	507
2022 Q3	$1K	Hold	18	–	–	﹤0.01%	502
2022 Q2	$2K	Hold	18	–	–	﹤0.01%	431
2022 Q1	$2K	Hold	18	–	–	﹤0.01%	443
2021 Q4	$2K	Hold	18	–	–	﹤0.01%	440
2021 Q3	$4K	Hold	18	–	–	﹤0.01%	390
2021 Q2	$9K	Hold	18	–	–	﹤0.01%	328
2021 Q1	$4K	Buy	+18	New	+$3.15K	﹤0.01%	403

Other funds holding GTBP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFS

Baskin Financial Services Toronto, Ontario, Canada $1.27B AUM 9.68% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TimeScale Financial's GTBP Position: Q2 2023 in Review

TimeScale Financial held its GT Biopharma (GTBP) position steady in Q2 2023 at 18 shares worth $171. The position accounts for ﹤0.01% of the portfolio, ranked #608.

TimeScale Financial first reported a position in GTBP in Q1 2021 and has held it in 10 quarters since. The position peaked at $9K in Q2 2021. 35 funds tracked by Wall St. Rank hold GTBP as of Q2 2023.

TimeScale Financial held 18 shares of GT Biopharma worth $171 as of Q2 2023.
TimeScale Financial left its GT Biopharma share count unchanged in Q2 2023.
GT Biopharma made up ﹤0.01% of TimeScale Financial's portfolio in Q2 2023, its #608 holding.
TimeScale Financial first reported a position in GT Biopharma in Q1 2021 and has held it in 10 quarters since.
TimeScale Financial's GT Biopharma position peaked at $9K in Q2 2021.
35 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2023.

Based on TimeScale Financial's 13F filing for Q2 2023, filed 27 Jul 2023.